Description
EACH FILM-COATED LUCILORLA TABLET CONTAINS:
Lorlatinib……………………25mg
INDICATION:
LuciLorla is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
DOSAGE AND USE:
Recommended dosage: 100 mg orally once daily.
Severe Renal Impairment: 75 mg orally once daily.
Tablets should be swallowed whole & not chewed or crushed.
STORAGE:
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Keep medicine out of the reach of Children.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION:
To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.
Reviews
There are no reviews yet.